Related Experiment Video
Updated: Sep 27, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Impact of Low-density Lipoprotein Cholesterol Levels on Outcomes in Nonvalvular Atrial Fibrillation: Results from the
Zhi-Zhao Li1,2, Xin Du2, Nian Liu2
1Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland).
Insights
In patients with nonvalvular atrial fibrillation (NVAF) not on lipid-lowering medication, lower LDL-C levels correlate with higher risks of stroke and cardiovascular events. This highlights the importance of considering baseline LDL-C in risk assessment for NVAF patients.
Area of Science:
- Cardiology
- Vascular Medicine
- Epidemiology
Background:
- Low-density lipoprotein cholesterol (LDL-C) reduction is crucial for cardiovascular outcomes.
- Nonvalvular atrial fibrillation (NVAF) is a significant risk factor for thromboembolic events.
- Understanding lipid profiles in NVAF patients is essential for risk stratification.
Purpose of the Study:
- To investigate the association between LDL-C levels and clinical outcomes in patients with NVAF.
- To analyze these relationships across different LDL-C quartiles.
- To explore the influence of oral anticoagulants (OAC) and statin use on these associations.
Main Methods:
- A prospective cohort study involving 19,515 patients, with 6,775 diagnosed with NVAF, followed for 5 years.
- Patients were stratified into four LDL-C quartiles at enrollment.
- Kaplan-Meier curves and log-rank tests were used to analyze event rates, considering OAC and statin use, and CHA₂DS₂-VASc scores.
Main Results:
- Hyperlipidemia was not an independent risk factor for stroke/thromboembolism or cardiovascular mortality in NVAF patients.
- In patients not on OAC and statins, increasing LDL-C levels were associated with a decrease in adverse events.
- This inverse relationship between LDL-C and events was more pronounced in patients without OAC and statins, and in those with higher CHA₂DS₂-VASc scores (≥2).
Conclusions:
- Among NVAF patients not on lipid-lowering therapy, lower LDL-C levels are linked to an increased risk of stroke/thromboembolism and cardiovascular mortality.
- The findings suggest a potential J-shaped or inverse relationship between LDL-C and adverse outcomes in specific NVAF subgroups.
- Further research is warranted to elucidate the complex interplay between LDL-C, lipid-lowering therapies, and cardiovascular risk in NVAF.
Abstract:
BACKGROUND Low-density lipoprotein cholesterol (LDL-C) reduction improves cardiovascular outcomes. This study investigates the relationship between lipid levels and outcomes in patients with nonvalvular atrial fibrillation by LDL-C quarters. MATERIAL AND METHODS Patients with atrial fibrillation were enrolled from 31 typical hospitals in China. Of 19 515 patients, 6775 with nonvalvular atrial fibrillation (NVAF) were followed for 5 years or until an event occurred. RESULTS Hyperlipidemia was not an independent risk factor for stroke/thromboembolism and cardiovascular mortality among patients with NVAF (hazard ratio 0.82, 95% CI 0.7-0.96, P=0.82). When patients were divided into quartiles according to LDL-C levels at the time of enrollment (Q1, <1.95; Q2, 1.95-2.51; Q3, 2.52-3.09; and Q4, >3.09 mmol/L), as LDL-C increased, events tapered off according to Kaplan-Meier curves for patients who were without oral anticoagulants and off statins (non-OAC; log-rank=8.3494, P=0.0393) and for those with oral anticoagulants (OAC; log-rank=6.7668 P=0.0797). This relationship was stronger for patients who were without OAC treatment and off statins than for those with OAC treatment. The relationship was not significant in patients with or without OAC and on statins (log-rank=2.5080, P=0.4738). This relationship also existed in patients with CHA₂DS₂-VASc scores <2 (log-rank=5.893, P=0.1167). For those with CHA2DS2-VASc scores ≥2 (log-rank=6.6163, P=0.0852), the relationship was stronger. CONCLUSIONS In patients with NVAF using standard or no lipid-lowering medication, low plasma LDL-C levels were related to an increased risk of stroke/thromboembolism and cardiovascular mortality.
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:26Atherosclerosis III: Management
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:30Coronary Artery Disease I: Introduction